Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evolus, Inc.    EOLS

EVOLUS, INC.

(EOLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EVOLUS, INC. : Regulation FD Disclosure (form 8-K)

11/19/2020 | 05:05pm EST

Item 7.01 Regulation FD Disclosure.

As most recently reported by Evolus, Inc. (the "Company") in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the Securities and Exchange Commission on October 29, 2020, the Company is a party to a U.S. International Trade Commission ("ITC") case which is entitled "In the Matter of Certain Botulinum Toxin Products", Investigation Number 337-TA-1145 (the "ITC Action").

On November 19, 2020, the ITC issued a notice extending the target date for their final determination of the ITC Action from November 19, 2020 to December 16, 2020.

As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about EVOLUS, INC.
01/05EVOLUS, INC. : Termination of a Material Definitive Agreement, Results of Operat..
AQ
2020EVOLUS : Provides Update on United States International Trade Commission Case
AQ
2020US ITC Blocks Imports of Jeuveau Wrinkle Treatment -- Bloomberg
DJ
2020Evolus Provides Update on United States International Trade Commission (ITC) ..
GL
2020EVOLUS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2020DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
2020EOLS INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Sh..
BU
2020THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
2020DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
2020EVOLUS : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Evolus, Inc. Investors of Impor..
BU
More news
Financials (USD)
Sales 2020 58,3 M - -
Net income 2020 -65,4 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,41x
Yield 2020 -
Capitalization 223 M 223 M -
Capi. / Sales 2020 3,83x
Capi. / Sales 2021 2,51x
Nbr of Employees 125
Free-Float 66,0%
Chart EVOLUS, INC.
Duration : Period :
Evolus, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLUS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7,13 $
Last Close Price 6,62 $
Spread / Highest target 66,2%
Spread / Average Target 7,63%
Spread / Lowest Target -39,6%
EPS Revisions
Managers and Directors
NameTitle
David Moatazedi President, Chief Executive Officer & Director
Vikram Malik Chairman
Alejandro Sabad Vice President-Operations
Lauren P. Silvernail Chief Financial & Accounting Officer
Rui Avelar Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
EVOLUS, INC.97.02%223
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148